- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (ARWR 0.89, 0.00, -0.11%) today announced that Douglass Given MD, PhD, MBA, has joined the Company's Board of Directors, expanding Arrowhead's Board to a total of six directors. Dr. Given is a biotechnology industry executive and investor with extensive experience in founding, operating, and financing companies for the successful development and commercialization of innovative technologies. Dr. Given is Chairman and CEO of Vivaldi Biosciences Inc., Chairman of VIA Pharmaceuticals, Inc., and an Investment Partner at Bay City Capital LLC.
"Dr. Given's appointment represents the accomplishment of another of our key corporate goals for the remainder of the year," said Dr. Christopher Anzalone, Arrowhead President and CEO. "Deep experience within the biotechnology and pharmaceutical industries is critical for Arrowhead as it transitions into a focused nanomedicine company, and Dr. Given will be a substantial contributor toward this. He has extensive operational experience at leading companies. From a business development standpoint, he has co-invested and/or executed partnerships with many major biopharmaceutical companies worldwide. We are very excited that Dr. Given will be a key member of our team as we continue to execute on our strategic initiatives."
Dr. Given said, "I was attracted because Chris and his colleagues understand that when you aim to commercialize a transformational technology like nanomedicine, you combine strategic focus, a financeable business plan, experienced development managers and capital with visionary technology disrupters like Mark Davis, Mauro Ferrari and Sam Stupp."
Dr. Given was formerly CEO and a director of NeoRx Corp., Corporate Sr. Vice President and Chief Technical Officer of Mallinckrodt Inc., and CEO and a director of Progenitor Inc. and Mercator Genetics Inc. He held positions as Vice President at Schering Plough Research Institute, Vice President at Monsanto/G.D. Searle Research Laboratories, and Medical Advisor at Lilly Research Laboratories.
Dr. Given's current association with Bay City Capital spans ten years, during which he has taken a leading role in identifying promising technology opportunities and creating value through company formation, development, and strategic transactions. Bay City Capital is a premier life sciences venture capital investment firm representing $1.6 billion in capital invested in over 85 companies. Dr. Given is also Chairman of the Visiting Committee to the Medical Center, Division of Biological Sciences and the Pritzker School of Medicine at the University of Chicago, a member of the Johns Hopkins Bloomberg School of Public Health Advisory Board, and a member of the International Advisory Council of the Harvard School of Public Health AIDS Initiative. Dr. Given holds an MD with honors and a PhD from the University of Chicago, and an MBA from the Wharton School, University of Pennsylvania. He was a fellow in Internal Medicine and Infectious Diseases at Harvard Medical School and Massachusetts General Hospital.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
For more information, please click here
The Piacente Group
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017